Technical Analysis for TELO - Telomir Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 4.25 | 4.68% | 0.19 |
TELO closed up 4.68 percent on Friday, November 1, 2024, on 46 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 11
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | N/A | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Wide Bands | Range Expansion | 4.68% | |
Down 3 Days in a Row | Weakness | 4.68% | |
20 DMA Resistance | Bearish | -3.63% | |
MACD Bearish Signal Line Cross | Bearish | -3.63% | |
Wide Bands | Range Expansion | -3.63% | |
20 DMA Resistance | Bearish | -12.37% |
Alert | Time |
---|---|
Up 5% | about 18 hours ago |
Possible NR7 | about 18 hours ago |
Fell Below Previous Day's Low | about 21 hours ago |
Up 3% | about 24 hours ago |
Up 2% | about 24 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Medication Stem Cell Chemotherapy Osteoarthritis Small Molecule Interleukin 17
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Medication Stem Cell Chemotherapy Osteoarthritis Small Molecule Interleukin 17
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 20.72 |
52 Week Low | 3.11 |
Average Volume | 130,107 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 5.41 |
20-Day Moving Average | 4.69 |
10-Day Moving Average | 4.42 |
Average True Range | 0.42 |
RSI (14) | 40.48 |
ADX | 18.68 |
+DI | 17.81 |
-DI | 26.99 |
Chandelier Exit (Long, 3 ATRs) | 4.56 |
Chandelier Exit (Short, 3 ATRs) | 5.30 |
Upper Bollinger Bands | 5.42 |
Lower Bollinger Band | 3.97 |
Percent B (%b) | 0.19 |
BandWidth | 30.74 |
MACD Line | -0.33 |
MACD Signal Line | -0.31 |
MACD Histogram | -0.0213 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.63 | ||||
Resistance 3 (R3) | 4.60 | 4.45 | 4.56 | ||
Resistance 2 (R2) | 4.45 | 4.35 | 4.46 | 4.54 | |
Resistance 1 (R1) | 4.35 | 4.30 | 4.40 | 4.38 | 4.52 |
Pivot Point | 4.20 | 4.20 | 4.23 | 4.21 | 4.20 |
Support 1 (S1) | 4.10 | 4.10 | 4.15 | 4.13 | 3.98 |
Support 2 (S2) | 3.95 | 4.05 | 3.96 | 3.96 | |
Support 3 (S3) | 3.85 | 3.95 | 3.94 | ||
Support 4 (S4) | 3.88 |